LUMEE Lumenis Ltd. (MM)

Lumenis Announces New Global VP of Research and Development YOKNEAM, Israel, Dec. 10 /PRNewswire-FirstCall/ -- Lumenis Ltd. has announced today that Mr. Igor Gradov has joined Lumenis as the Global Vice President of Research & Development. "I am extremely pleased to welcome Igor to our team, in a position which I view as a key strategic position in our company's future. Having a seasoned executive such as Igor, with 25 years of successfully managing multi-disciplinary and international engineering and scientific teams is a great asset to us and to our customers, that expect us to continue to be leaders in our markets," stated Mr. Avner Raz, President and Chief Executive Officer. Mr. Gradov has spent his career dedicated to the design, development and product introduction of light based medical products and technologies in the market segments of Dermatology, Ophthalmology, Dentistry and General Surgery. Mr. Gradov previously held positions as Director of Engineering at Coherent Optical Division, Director of Research & Development at VISX Inc., Vice President of Engineering for Palomar Medical Technologies, Vice President Technology Development at Emory Vision Correction Group, and most recently as COO of Luxano AB, Sweden. About Lumenis Lumenis develops, manufactures, and markets state-of-the-art proprietary laser and intense pulsed light devices. Its systems are used in a variety of aesthetic, ophthalmic, surgical and dental applications, including skin treatments, hair removal, non-invasive treatment of vascular lesions and pigmented lesions, acne, psoriasis, ENT, gynecology, urinary lithotripsy, benign prostatic hyperplasia, open angle glaucoma, diabetic retinopathy, secondary cataracts, age-related macular degeneration, vision correction, neurosurgery, dentistry and veterinary. For more information about the Company and its products log on to http://www.lumenis.com/ The statements in this press release that are not historical facts are forward-looking statements which are subject to risks and uncertainties. The Company's actual results could differ materially from those anticipated in the forward looking statements based on a variety of factors, including, among others: uncertainties with respect to market acceptance of the Company's products, obtaining regulatory approvals for new products or for the sale of existing products in new markets and enforcement of intellectual property rights; risks associated with competition and competitive pricing pressures, economic conditions generally, the Company's international operations and the Company's ability to integrate its operations with those of acquired businesses; the outcome of the Securities and Exchange Commission investigation and several securities class action lawsuits to which the Company is subject; uncertainties relating to the Company's continuing liquidity; and other risks detailed from time to time in the reports filed by Lumenis with the SEC, including its annual report on Form 10-K and quarterly reports on Form 10-Q. Contacts: Kevin Morano CFO 212-515-4187 DATASOURCE: Lumenis Ltd. CONTACT: Kevin Morano, CFO of Lumenis Ltd., +1-212-515-4187 Web Site: http://www.lumenis.com/

Copyright